Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. - Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2016)